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Protocol and beyond: practices of care 
during a Tuberculosis vaccine 
clinical trial in South Africa1
Justin Dixon
 Social Anthropology, University of Cape Town, Private Bag X3, Rondebosch 7701, South Africa
dxnjus001@myuct.ac.za
Much of the current social science literature on the clinical trials industry focuses on the profit-seeking practices adopted by 
pharmaceutical companies and the contract research organisations they employ to enable the mass production and distribution 
of their products. However, what the current literature demands is further ethnographic engagement with the particularities of 
the diseases being investigated, the local contexts and histories in which they are entwined, and how these impact the affective 
relationships between clinical research organisations and their participants. On the basis of ethnographic research with a non-
profit clinical research organisation specialising in TB vaccinations in South Africa, I argue that the complexities of TB mean 
that research into it necessitates frequent and often intimate interactions with research participants. These were perceived by 
researchers to yield opportunities to take an interest in the physical and psychosocial wellbeing of research participants which 
went beyond and sometimes ran into conflict with the requirements of protocol. The aim of this paper is to advocate more 
finely tuned attention to the challenges posed by the clinical trials industry today, an attention sensitive to the particularities of 
the contexts of clinical trials. 
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Introduction
The clinical trials industry, having emerged in response to a 
global ‘need’ for data procured from human bodies, has 
recently attracted the attention of a number of social scien-
tists. The primary focus of this increasing body of literature is 
the exploitative practices adopted by ‘Big Pharma’ in the pur-
suit of profit and, in particular, the ways in which it is able to 
enlist the bodies of impoverished people and populations 
worldwide to this end (Adams et al. 2005; Fischer 2009; Pet-
ryna 2007, 2009). In this paper, I argue that whilst these cri-
tiques are highly important, further ethnographic attention is 
required to the particularities of the diseases at which much 
clinical research is directed, the local contexts and histories in 
which they are entwined, and how these impact the affective 
relationships between clinical research organisations and 
their participants. My contention, one which is recom-
mended by current literature on practices of care (e.g. Mol 
2008), is that these are important to consider if we as critical 
enquirers are to understand the clinical trials industry and the 
challenges it currently faces, especially as more and more 
clinical trials are being relocated to resource-poor regions of 
the world.
After a brief elaboration on the relevant literature below, 
in order to substantiate these claims I draw upon ethno-
graphic research conducted with the Tuberculosis Research 
Organisation (TRO), a non-profit research organisation in 
South Africa specialising in clinical trials on tuberculosis (TB) 
vaccines. Detailing some of TRO’s day-to-day operations, I 
argue that conducting clinical research on TB in South Africa 
– and childhood TB in particular – necessitates frequent and 
often intimate interactions with often incredibly impover-
ished research participants (in the context of the ‘follow-up 
visits’ and the ‘case verification ward’). These interactions 
were regarded by TRO’s researchers as yielding opportuni-
ties to take an active interest in the physical and psychosocial 
wellbeing of their research subjects which often went beyond 
the requirements of protocol (cf. Human 2011). As I shall 
demonstrate, some of the most pressing challenges TRO’s 
researchers faced as they tried to conduct clinical research in 
the midst of often great suffering pertained to how to 
approach the ‘extra-protocol’ provision of care for research 
participants. But these challenges cannot easily be abstracted 
from the particularities of TB as a historical phenomenon in 
South Africa, or from the legacy of apartheid governance 
which has left the majority of TRO’s participants in near-
absolute poverty. The importance of context in the case of 
TRO suggests that the trajectory of the literature on clinical 
trials should be broadened to include more ‘thick’ ethno-
graphic accounts, ones which will hopefully let us suggest 
some ground-level solutions to particular challenges in partic-
ular localities. 
Background
The clinical trials industry brings together in an uneasy rela-
tionship the global neo-liberal economy, international phar-
maceutical companies and regulatory bodies, independent 
research organisations, and low-income people/populations 
(Adams et al. 2005; Fischer 2009; Petryna 2007, 2009). The 
commodity that lies at the heart of this thriving industry is 
data procured from human subjects, which, when converted 
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into ‘go-aheads’ from global regulatory bodies (e.g. the US 
Food and Drug Administration [FDA]) to mass produce and 
distribute prospective pharmaceutical bio-products, are 
worth millions or even billions of dollars in profit (Rennie 
2010:114). Thus it is unsurprising that, as with numerous 
other ‘natural’ resources, people compete with one another 
for a share of the profits. One of the major structural read-
justments to the clinical trials industry in the last three dec-
ades is pharmaceutical companies’ outsourcing their clinical 
trials to independent, contract-based research organisations 
(CROs). Competition among these companies to secure con-
tracts is fierce because their survival depends on the ability to 
get the job done efficiently and cheaply. Given that the most 
‘ideal’ bodies for clinical research – ones which are relatively 
‘treatment-naive’ – are to be found in resource-poor envi-
ronments, a staggering number of clinical trials contracts have 
been awarded to research organisations geographically out-
side the industrialised centres of science (Adams et al.
2008:317). 
On the one hand, participants in clinical trials are usually 
paid for their participation and, moreover, often enjoy access 
to healthcare resources they would otherwise be denied 
(Benatar 2002:1135). On the other hand, as authors have 
observed, these considerations, and efforts to adapt the neo-
liberal central pillars of ethical research – e.g. informed con-
sent, protection from harm, minimising risk, confidentiality – 
to the socio-cultural particularities of clinical research set-
tings, are marked by the gaping structural inequalities that 
exist between researchers and vulnerable people and popula-
tions (Adams et al. 2005:268; Fischer 2009; Petryna 2009; 
Benatar and Upshur 2010). Indeed, as Petryna (2007:294) 
astutely notes, ‘Big Pharma’ is now powerful enough to 
manipulate the global variability in regulatory standards to fill 
their clinical trials, and ultimately get their products on the 
market. Seen against the backdrop of such over-arching 
profit-seeking practices, it is perhaps unsurprising that any-
thing more than a face-value ethic of care for research sub-
jects seems to be, although not altogether absent (see, for 
instance, Fischer 2009), at least considerably undernourished. 
These are important concerns, and they are yet to be given 
the attention they merit in biomedical forums with a focus on 
the global reach of contemporary clinical trials.
Yet, recent anthropological scholarship on practices of 
care suggests that this expanding body of literature on the 
clinical trials industry would be complemented by further 
ethnographic attention to particular localities of clinical 
research. Where the latter body of literature has drawn 
attention to the neo-liberal vocabulary legitimising the global 
conduct of clinical trials, the former, along a similar theoreti-
cal vein, has challenged the “logic of choice” as the paradigm 
for formal healthcare provision (Mol 2006, 2008; Mol, Moser 
and Pols 2010; Henderson 2011; Hardon et al. 2011). Contra 
the “logic of choice” paradigm, Annemarie Mol (2008) impor-
tantly argues that healthcare is not the product of ‘rational’, 
‘informed’ choices made on the part of individual patients nor 
does it have a clear-cut beginning and end. She demonstrates 
that in reality, care-provision involves on-going, obstacle-rid-
den processes of negotiation and “tinkering” (Mol 2008:14) 
between multiple actors, including patients, their families, 
medical professionals, and – since Mol is influenced by actor-
network theory (e.g. Latour 1999) – various medical tools, 
technologies and procedures. Care is a relational, processual 
phenomenon. Mol (2008:9) argues that the particularities of 
these processes are context-specific, inevitably varying from 
location to location. Therefore, creating productive and effi-
cacious solutions to the challenges of providing ‘good’ care 
requires close attention to the local ecologies of care which 
enable, and inhibit, particular initiatives. 
The affective relations between clinical researchers and 
their participants are undeniably marked by the wider politi-
cal-economic processes bringing them into frequent contact. 
Nonetheless, the above considerations recommend further 
ethnographic engagement with the particularities of context – 
both human and non-human – informing the challenges faced 
by clinical researchers on the ground as they try to balance, 
on the one hand, the arguably inherent exploitation entailed 
by clinical trials, and, on the other, the subjectivities and 
healthcare needs of impoverished research participants. In 
order to address this gap, I turn the reader’s attention to the 
current state of the tuberculosis (TB) epidemic in South 
Africa and, subsequently, to the endeavours of the TRO as 
they conducted a clinical trial designed to test a prospective 
TB vaccine on the bodies of infants living in a rural region of 
the country. 
TB vaccinations research at TRO
Tuberculosis (TB) is re-emerging as one of the most prevalent 
infectious diseases in the world. In 2007, 1.3 million were 
killed by TB alone and an additional 456,000 were killed who 
were already co-infected with HIV/AIDS (World Health 
Organisation 2009). The vast majority of positive TB diag-
noses are made in low-income countries, where the condi-
tions under which the disease thrives – inadequate food 
security, unhygienic and crowded living conditions, and poor 
access to healthcare – are abundant (Benatar and Upshur 
2010:1215). Despite being a democratic republic since 1994, 
a middle-income country and having a large number of peo-
ple in high-income brackets compared to low-income coun-
tries, South Africa remains haunted by a legacy of apartheid 
governance that left millions in almost absolute poverty. Thus, 
in conjunction with an already critical epidemic of HIV and 
AIDS, which compounds the effects of TB, it is perhaps 
unsurprising that certain provinces in the country have 
amongst the highest TB morbidity and mortality rates in the 
world (Naidoo and Mwaba 2010:1324). To make matters 
worse, although it was once thought that Africa had a com-
paratively low rate of drug resistant strains of TB compared 
to other continents, the high incidence of patients ‘defaulting’ 
on their drug-therapies has ensured outbreaks of several mul-
tiple-drug-resistant strains of TB (Wallengren et al. 2011).
Notwithstanding pharmaceutical companies’ compara-
tively low level of interest in TB, significant time and 
resources are being concentrated on managing the disease 
worldwide. This has involved the development not only of 
post-diagnostic antibiotics – which are unfortunately becom-
ing less and less effective given the high incidence of drug-
resistant TB – but also research into vaccinations to preclude 
the onset of TB disease in the first instance. The Bacilli Cal-
mette-Guerin (BCG) vaccine, which has been an integral part 
of the TB response since its introduction in the first half of the 
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20th century, is currently the only vaccine on the market. 
However, it is widely thought to be insufficient as a self-stand-
ing TB preventative. Thus, a primary goal at present is the 
production and distribution of a supplementary booster vac-
cine which will increase the worldwide efficacy of the BCG. 
TRO is currently trialling TB vaccines trials in South Africa 
in the interests of testing such a vaccine. TRO’s endeavours 
necessitate a wide institutional base and a regular flow of 
organic matter between its main laboratory (located in a large 
city in South Africa) and its field-project office in a town about 
an hour’s drive away. The location of the field project office 
where the trials are conducted was chosen because of its 
close proximity to the pool from which research participants 
are drawn, a several-hundred-thousand strong rural popula-
tion. The field-project office – where I conducted most of my 
ethnographic research – is located within the premises of a 
public hospital which specialises in TB diagnosis and treat-
ment. It incorporates a vaccine trials clinic, a case verification 
(CV) ward for suspected cases of childhood TB, an immunol-
ogy laboratory, and various administrative offices. It also has 
upward of thirty vehicles for collecting organic matter from, 
and delivering it to, the laboratory in the nearby city, as well 
as picking up and dropping off the donors of that organic mat-
ter in and around local clinics in the surrounding rural region.
TRO’s research is made incredibly difficult because of the 
complexities inherent in conceptualising and diagnosing TB, 
especially in the infants and young children on whom the 
majority of TB vaccines research is conducted. A great many 
signs and symptoms are associated with childhood TB: weight 
loss, a cough lasting more than two weeks, certain blotches 
on a chest X-Ray, positive quantiFERON or Mantoux skin test 
(both of which test for latent TB), and positive ‘TB culture’. 
And an infant may, as far as anybody can actually know, have 
TB disease, and yet display only some of these symptoms and 
signs. Consequentially, diagnostic “algorithms” – tailored to 
context (Hatherill et al. 2009) – are used in the research con-
text. These take as inputs various clinical, radiological and 
immunological signs and symptoms and give as outputs either 
positive or negative diagnoses of TB disease. More specifi-
cally, as a criterion an infant may be required to display, say, at 
least one of each type of sign or symptom – radiological, 
immunological, and clinical – to be diagnosed as having TB 
disease. In this way, researchers can be certain that there is a 
very high likelihood that a particular infant, despite not dis-
playing various other signs or symptoms, has TB disease.
Sponsored by a large US-based non-profit organisation, 
the TRO is currently conducting (phase IIb) clinical trials into 
the safety (and, as a secondary objective, efficacy) of a partic-
ular candidate booster vaccine for the BCG.2 This meant that 
not only are TRO’s researchers vigilant for signs of TB disease 
in their research subjects, but also other ‘adverse events’ of 
varying degrees of severity that are causally linked to the trial 
vaccine. In this safety study, several thousand infants, enlisted 
from prenatal clinics around the rural communities, were 
vaccinated over a staggered time period of two years. After 
receiving the trial vaccine, each infant is to be ‘followed up’ 
regularly for a period of two years. Thus, the trial is sched-
uled to run for approximately four years. During that period, 
the infants’ mothers – or relatives – are expected to make 
the infant available for several clinic and ‘follow-up’ visits, the 
purpose of which is to assess the infant’s wellbeing and to 
conduct various tests and examinations. Aside from remain-
ing vigilant for adverse events, if, during these visits, reason is 
found to suggest that an infant may have TB, the mother or 
relative is requested to attend the CV ward on a prescribed 
date for a period of 48 hours, where the infant is subjected to 
a series of tests for childhood TB. Throughout the trial, driv-
ers transport blood samples and other organic matter at least 
daily to and from TRO’s urban laboratories, where the results 
of the tests are determined. The data collected by the home 
visit staff and clinics, as well as the results of the tests con-
ducted in the CV ward, constitute the inputs into TRO’s trial 
algorithm and, more generally speaking, the data which is ulti-
mately used to determine whether the vaccine is safe for 
mass consumption.
Following protocol and beyond:  
complexities on the ground
While TB vaccinations research appears daunting even on 
paper, especially given the quantity and variety of clinical data 
required to make a diagnosis, in practice it is a colossal task. 
Completing it requires massive amounts of planning, a large 
number of staff, as well as abundant time and resources – 
which, I was frequently told, TRO is hard-pushed to maintain. 
Moreover, as I became more acquainted with the goings-on 
in and around TRO’s field office, I quickly came to realise that 
not only is the enactment of protocol on the ground rife with 
complexities, challenges, and contestation invisible from the 
abstract point of view of the protocol, it is also punctuated by 
the co-enactment – and the problems that arise therewith – 
of what might be called ‘extra-protocol’. For, in the midst of 
following the frequent, demanding, and often intimate 
requirements of protocol, the physical and psycho-social 
wellbeing of research participants (beyond that ‘relevant’ to 
the trial itself) has become an active, albeit contested and 
problematic, issue among TRO’s on-site staff. The loci of 
these issues are the points at which there is the most direct 
social interaction between TRO’s research staff and their par-
ticipants: the ‘follow-up’ visits and admissions to the CV 
ward.
Follow-up visits
An integral part of TRO’s research protocol is the ‘follow-up’ 
a.k.a. ‘home’ visits. As I mentioned before, the purpose of 
these visits, according to protocol, is to determine whether 
or not any of the enrolled infants are showing signs that they 
have TB disease or any other ‘adverse events’, in which case 
they need to attend the CV ward for further tests or treat-
ment. This is no easy task. Given the large sample of partici-
pants required by TRO’s phase IIb trials – several thousand 
infants, in this case – and the staggered time period over 
which they have been given the trial vaccine, several teams of 
field researchers, co-ordinated by various administrative staff, 
head out into the surrounding region each day to track down 
a specified number of the enrolled infants. Each team has at 
least two members: a driver, who is responsible for finding 
2. TRO is sponsored by several other institutions for different projects.
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the infants’ homes, and another researcher, who conducts 
the home visit itself. A third team member is often included 
to make the process run more smoothly and efficiently. 
One of the first things which caught my attention when I 
went out into the field with one of the home visit teams was 
how common a sight the TRO vehicles – white, with a mem-
orable logo on the side – and research staff were to the peo-
ple living in the settlements and farms around the field office. 
As we drove through one settlement, barely more than a 
passing glance was spared in our direction, and the few we 
received were mostly directed at me, suggesting that it was 
only because I was not a regular member of the team. When I 
asked Yolanda – one of the field researchers – about this, she 
said that while it took a significant amount of time before the 
constituents of the region were accustomed to TRO’s pres-
ence, they are now, years later, such a familiar sight that they 
are now most frequently referred to as “the TB people”. Per-
haps as a consequence of this nurtured degree of familiarity, 
an air of routine permeated the interactions with infants’ 
mothers or relatives as we made our way through the list of 
that day’s infants. The infants’ mothers or relatives, after 
meeting the TRO vehicle outside, were quick and, seemingly 
unhesitant, to allow the team into their homes and to make 
physical contact with the infants. Often, they were even will-
ing to extend exchanged pleasantries into more personal 
chats regarding the ins-and-outs of their day-to-day lives. 
These exchanges suggested an intimacy between researchers 
and the areas in which they worked which I had not expected 
to see in the middle of what is effectively a bio-scientific 
experiment. 
Nonetheless, all parties knew what the follow-up visit 
team’s presence entailed (see above). Guiding this task is the 
follow-up visit form, a series of questions and boxes to be 
filled in, most of which are to be answered on the basis of the 
testimony of the infants’ mothers or relatives. Questions 
include whether the infant has been in contact with anyone 
with TB recently, whether they have been coughing exces-
sively, and, if so, for how long, and if they have had other 
medical problems or been taking any medicines since the last 
visit. There are also some pragmatic questions to be 
answered, such as how many attempts it took to track down 
the infant, the relation of the infant to the present carer, and a 
space for any further comments. Perhaps the most character-
istic aspect of the visit, however, and by far the most difficult 
to accomplish, is the weighing of the infant. This is distressing 
for the infant because, in the interests of procuring a ‘reliable’ 
measurement, the infant needs to be stripped of their clothes 
– a necessity made even worse by the fact that it was winter 
at the time of my fieldwork. In one home, it took several 
attempts for Yolanda, Lucinda, and the mother to convince an 
increasingly distraught infant to stand up on TRO’s pair of 
scales long enough to procure a reading. Even then, the infant 
would not stand still enough and so they had to add a bowl to 
the scales – one used to weigh younger infants who are una-
ble to stand of their own accord – to get the desired meas-
urement.
Asking the prescribed questions and weighing the infant 
is, in effect, all that the study protocol requires of the follow-
up teams. However, having sat in on one of the weekly “TB 
Reviews” – a seminar, on this occasion conducted by Dr van 
Zyl, which TRO’s staff are strongly advised to attend – I was 
aware that the follow-up teams are also implored by the 
study doctors to take a holistic view of the infant during the 
home visit, one which often necessitates a critical eye for 
context that transcends the bare requirements of the form. 
This includes, for instance, whether they live close to a sewer, 
are malnourished, have foetal alcohol syndrome – even 
whether or not they are teething, etc. It also includes subtle-
ties of speech, in and between questions, which hint at mat-
ters of medical concern. To an extent, taking account of these 
additional and often subtle contextual factors is important 
from the point of view of the study itself. Given that teething, 
malnutrition, and foetal alcohol syndrome, for instance, can 
affect the weight of the infant – and in a manner not necessar-
ily related to TB – if the follow-up team can pick up on these 
details of context then there may be reason to spare the 
time-and-resource-consuming task of bringing the infant into 
the CV ward for extensive testing. Moreover, because TRO’s 
current study is designed to determine the safety of a vaccine, 
it is even more relevant than in other studies to take stock of 
any problems and additional observations, no matter how 
apparently small or insignificant, which may be related to the 
trial vaccine.
The holistic and context-specific awareness required by 
the field teams’ work demonstrates that the ‘objectivity’ of 
scientific practice is often grounded in a simultaneous need to 
remain sensitive to the contingencies of the everyday (Latour 
and Woolgar 1987; Mol 2006). However, another important 
reason for maintaining a critical, holistically trained eye 
throughout the follow-up visits, I was told, is that the home 
visits, and the intimacies they entail, yield occasions to give 
healthcare and support for infants that the mothers or rela-
tives may not otherwise have access to or ask for. Although 
other study doctors and co-ordinators made very similar 
comments, Dr van Zyl advocated this approach most vocally:
What I was trying to implore them to do [in the TB 
Review] was to look beyond what they have to look 
for, because even though they’re over to screen for 
TB and that sort of thing ... sometimes some of 
these kids might not get seen by someone with 
some sort of medical background ... If there are 
other things to identify, I’d like them to use it as an 
opportunity to screen for other things too – I’m 
sure Johan and Chrizane would agree as well ... It’s 
so important that any time they have contact with 
anyone who has some insight into healthcare and 
links to resources that these opportunities get used 
as far as they possibly can.
With the current emphasis in policy and research on the role 
of the patient and the ‘choices’ they make as consumers of 
healthcare, it is easy to lose sight of the agencies of medical 
professionals in offering care where care is potentially needed 
(cf. Henderson 2011:178-9). The context sensitive approach 
to the challenges of healthcare provision urged by Annemarie 
Mol (2008), on the other hand, recommends that researchers 
maintain a holistic purview which acknowledges such agen-
cies – even in the midst of bio-scientific experiments. 
Although this is by no means a general finding (see, eg., some 
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of Petryna (2009) and Fischer’s (2009) observations), there 
was a clear feeling on the part of TRO’s study doctors that 
they had a responsibility for the wellbeing of their participants 
beyond the generic safeguarding required by study protocol. 
Picking up on often subtle bodily and contextual signs is 
not easy in practice. As Yvonne, head of TRO’s on-site quality 
assurance (QA) department, explained to me: 
You’re sending field workers with no medical 
background into a situation to use an algorithm ... 
or a questionnaire, yes/no, ask a question, get an 
answer. The challenge is ... you ask the question, 
and the human that’s sitting in front of you in this 
situation in the environment they are in, they see 
this as an opportunity to discuss things, or to find 
help, and they’re dealing with someone who can’t 
help them, who doesn’t have the insight to pick up 
the hints or the medical information that is given in 
those few sentences, for them to make an informed 
decision and answer ... so I think they’re struggling.
Whilst TRO’s follow-up teams are currently undergoing train-
ing by the QA department to improve their holistic, context 
specific awareness when in the field, it is beyond the scope of 
TROs resources to send trained medical professionals into 
the field to conduct the follow-up visits. Hardon et al.
(2011:196) found that in under-resourced HIV testing facili-
ties in East Africa, “the dynamics of care … are shaped by the 
specificities of the care provided” and “professional training 
and human resource constraints.” Unable to provide the 
‘ideal’ degree of medical expertise, the field teams, in the 
midst of fulfilling the requirements of protocol (i.e. complet-
ing the “follow-up” form), nonetheless offer a unique, place-
specific form of care for TRO’s participants. Identifying the 
signs that ‘home remedies’ are not working, recommending 
visits to the local clinic, offering to drive them to the clinic and 
back again – these are but a few of the practices of care I wit-
nessed the teams negotiating with the day-to-day require-
ments of protocol. For the most part, these practices are 
entirely ad hoc. As Yolanda put it, “when you leave the office 
you don’t know what’s going to happen, you only know when 
you get there.” But they are nonetheless valuable contribu-
tions to TRO’s ‘extra-protocol’ endeavours. 
TRO’s field researchers are also faced with another chal-
lenge, one that arises from the conjunction of an impover-
ished socio-economic environment and the intimacies 
necessitated by TB research: the requirement by the doc-
trines of Good Clinical Practice (GCP) – cemented in law by 
the Children’s Act (2005) – to report cases of neglect and 
physical abuse. TRO’s field teams are generally viewed as 
being in a position to notice such instances: being allowed 
into the infants’ homes, interacting with mothers and rela-
tives and, perhaps most revealing of all, seeing the infants 
naked. Unlike the bodily and contextual signs discussed above 
– many of which are framed as subtle, esoteric, requiring a 
‘trained’ gaze – the latter, especially the phenomenon of 
physical abuse, are framed as relatively transparent, immedi-
ate, incumbent upon the field researcher’s senses. Accord-
ingly, TRO takes this issue very seriously. Yvonne argued 
passionately that protecting their research participants from 
instances of physical abuse is, and should continue to be, 
TRO’s long-standing concern:
Now that you’re entering that environment ... I 
mean this is something that we’ve always thought 
about ... [It’s] impossible, actually, if you think about 
it, given what we know about our communities, not 
to know that kids are being abused, and what’s 
going on in these homes.
 
However, during the time I spent with TRO’s QA department 
and research staff at the field office, I became aware of a gen-
eral perception that the follow-up teams encounter cases of 
severe neglect and abuse, but do not often report them, if at 
all. As Yvonne articulated the matter:
But we’ve never heard anything back from our field 
workers that, you know, where they’ve found 
instances of abuse ... very seldom would something 
like that come up. We think they see it, they hear 
about it, but they sort of ignore it because it’s not 
part of their business, and they don’t want to get 
involved. 
In the days I spent out with one of the follow-up teams, I wit-
nessed quite some perseverance on their part in probing 
these signs of abuse – often asking infants’ mothers, as inno-
cently as possible, about this cut or that bruise. This led me to 
question the extent to which the dichotomy which has been 
forged between the relative opacity of certain medically rele-
vant signs and signals, and the relative transparency of abuse – 
and, to a lesser extent, neglect – does justice to the ambigui-
ties of what constitutes ‘abuse’ or ‘neglect’. Certainly, the dif-
ference between ‘neglect’ and the inscription of apartheid 
legacy into the skins of TRO’s participants is as thin as a hair’s 
breadth. But even in the case of ‘abuse’ – which is arguably 
just as inseparable from the legacy of apartheid – it is not 
always a straightforward matter to distinguish a bruise left by 
the hand of an abusive father and one caused under more 
benign circumstances. 
Nonetheless, a number of incidents involving TRO’s 
enrolled infants – one involving a child being used as a human 
shield against an abusive husband – are cited as examples of 
the follow-up teams’ failure to report more blatant cases of 
physical abuse. Rather than uncritically endorsing what is 
required by the Children’s Act in these instances, however, 
the realities lived by TRO’s field researchers invite us to chal-
lenge the notion that the requirements articulated by legal 
doctrines (such as the Act) are unambiguously ‘good’ or 
‘right’ in all times and places. TRO’s field teams have, over 
time, clearly earned a measure of trust with many constitu-
ents of the region, not only being allowed into their homes 
and their lives, but also to make physical contact with their 
children. These fragile relationships act as a medium through 
which healthcare can be provided, some of which goes 
beyond the requirements of research protocol. While this 
does not exempt TRO’s follow-up teams from legal con-
straints, these are relationships which would be threatened 
were TRO’s field workers known for ‘telling’ on infants’ rela-
tives. Moreover, some of the areas where TRO’s participants 
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live are incredibly dangerous. One of the follow-up teams 
recently witnessed a stabbing directly outside the TRO vehi-
cle, after which the perpetrator held the knife up to the win-
dow and said, “I know who you are, and I’ll get you next.” 
Working in such environments, TRO’s researchers have their 
own safety to consider. Thus, the requirements of the Chil-
dren’s Act (2005), whilst perhaps necessary, are not an indis-
putable ‘good’ enabling TRO’s researchers to intervene in 
undesirable situations. Following Mol (2008), who highlights 
the efficacy of non-human as well as human actors, we should 
instead view legal doctrines such as the Children’s Act as con-
stituents of complex ecologies of care, the effects of which 
(see Mol 2006:412) vary from place to place and from time to 
time.
The case verification ward
One morning, I found myself regretting having accepted 
Monique’s invitation to observe the goings-on in the CV 
ward’s “treatment room”, located down the hall, and 
through a set of swinging doors, from the ward itself. This 
was not only because of the early start it entailed. The infants, 
who had been admitted into the CV ward the previous day, 
were undergoing a procedure called “sputum induction”, 
designed to procure a sputum sample which can be tested for 
TB disease. This is necessary because, unlike adults, infants 
are unable to cough up a sample on demand, and so the spu-
tum, rather than being voluntarily coughed into a tube, has to 
be ‘induced’. Whilst the nurses performing the inductions 
that morning, Monique and Klara, chatted amiably, intermit-
tently alerting me as to what they were doing, I watched the 
procedure time and again with a mixture of fascination and 
anguish. After the infant has had the contents of their chests 
‘loosened’ via the attachment of a nebuliser mask (assisted by 
the mother), the nurses would hold the infant down securely 
on the treatment table before lodging a thin tube, attached at 
its other end to a suction machine, up the infant’s nose and 
down and into its throat. As soon as the tube is in place, spu-
tum – and often a measure of blood – flies up the tube and 
into a test tube as the suction takes effect. The process was 
unpleasant to witness but it was of course far more of an 
ordeal for the infants, especially given that their mothers 
vacated the room as soon as the nebulising process was com-
plete (see also Blake 2007).
Sputum induction is among the least pleasant of the highly 
structured regimen of tests and examinations the infants 
undergo during the 48 hours in the ward. Often the mothers 
or relatives simply fail to arrive with the enrolled infants, and 
it falls to the follow up visit teams to try and track them down 
again. However, in the cases of those who do attend the CV 
ward, rarely, if ever, is the protocol interrupted. On the day 
of admission, the majority of the study nurses’ time is spent 
helping the mothers and infants to get settled into the ward. 
Each mother and infant is allotted an open cubicle with a bed 
and a cot and are given the time to meet the other mothers 
and infants with whom they will be sharing the next 48 hours. 
Such introductions and most of the subsequent interactions 
usually take place in the CV ward’s large kitchen area or in 
front of the TV situated nearby. Throughout the rest of the 
day, the infants are given an HIV and Mantoux skin test and 
are taken for an X-ray in the radiology department. They are 
also weighed again. At about 4 o’clock on the morning of day 
two, after a four hour “starve”, the infant has their first visit 
to the treatment room for a “gastric lavage”. This has the 
same purpose as the sputum induction although it involves a 
slightly different method. Subsequently, and after a “milk 
feed”, the infants are starved for another four hours before 
their second and final visit to the treatment room for the 
aforementioned sputum inductions. Immediately afterwards, 
and to conclude the most gruelling ordeals of the day, the 
infants undergo a quantiFERON blood test. Later that day, 
they are visited and examined by a clinical doctor, who, after 
checking through their case files to make sure nothing is 
amiss, signs the CV ward discharge form. The infants are dis-
charged the next morning, and the mothers are allowed to 
take them home again, where they await a call or visit from 
TRO’s researchers to alert them of the results of the tests 
and procedures of the stay.
Despite the unpleasantness of some requirements of the 
trial, and the inconvenience to the mothers of having to stay 
in the CV ward for 48 hours, there is the benefit of the close 
proximity to healthcare resources throughout. As Samsky 
(2011:412) notes, the line between experiment and care in 
the clinical trials industry is especially thin in instances where, 
as with TRO, the trials are conducted on the premises of 
larger medical facilities. Whereas the day-to-day operations 
of the follow-up teams (both protocol and extra-protocol) 
were inhibited by a lack of time and resources, in the CV 
ward medical expertise and resources were considerably 
more available. As in the hospital in the Netherlands where 
Mol (2008) conducted her ethnographic research, to my eye 
the healthcare relations enacted within the CV ward were 
comprehensive and largely heart-warming, although not free 
of challenges and conflict (cf. Greenhough 2010:137). 
Given that there is a very real chance that some of TRO’s 
enrolled infants will have potentially life-threatening TB dis-
ease, TRO cannot simply send an infant back home if a posi-
tive diagnosis is made. Treatment must be given. To that end, 
the close proximity of TRO’s field office to the host hospital’s 
clinical doctors and treatment facilities is crucial. The infants 
are visited by a clinical doctor (as opposed to an academic 
one) for clinical purposes. Occasionally, the clinical doctor is 
one of TRO’s own, but mostly the host hospital’s Dr Gilbert 
takes charge of the clinical component of TRO’s infants’ stays. 
Such are the consequences and worry of failing to pick up 
cases of TB disease that Dr Gilbert does not use TRO’s trial 
algorithm to determine whether an infant is to be treated for 
TB disease. This is because childhood TB disease is so easy to 
‘miss’, given the varying and often subtle signs and symptoms 
by which it manifests, that while ‘accuracy’ is the goal of the 
trial, in a clinical context doctors are more likely to err con-
sciously towards over-diagnosis. As Dr Janssen remarked to 
me, “as a clinician, if you're worried, rather put them on TB 
treatment than miss it, and have them coming back with TB 
meningitis or something.” Thus, the infants are subjected to 
two diagnostic algorithms during their stay in the CV ward: 
the trial algorithm for the study, and the more cautious Kibel 
system that Dr Gilbert uses to determine whether they 
should be treated for TB disease.3 Although positive diag-
noses are in the minority and most infants are discharged 
from the CV ward after the normal 48 hours, infants who are 
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diagnosed with TB disease are often admitted to the hospi-
tal’s children’s ward for a minimum of six months of extensive 
treatment. In particularly severe cases, infants are not even 
permitted to finish TRO’s tests before being admitted into 
the children’s ward. As Dr Gilbert divulged to me, one 
infant’s lungs, recently, were in such bad condition that they 
were admitted to the hospital’s children’s ward almost imme-
diately after being admitted to the CV ward. Thus, infants 
enrolled in TRO’s trials are more likely than other infants in 
the surrounding rural region to be diagnosed and treated for 
one of the most prolific killers in South Africa today.
The CV ward’s medical professionals seek to identify and 
manage other diseases as well as TB. Much like the follow-up 
teams’ “holistic” awareness, the CV ward’s nurses maintain a 
critical eye for medical matters that transcend the bare 
requirements of protocol. TRO’s participants often arrive in 
the CV ward with ailments that require medical attention, or 
may develop them at some point throughout their 48 hour 
stays. As Monique explained to me, however, given that the 
primary purpose of the CV ward is the conduct of a bio-sci-
entific experiment, which requires that ‘variables’ be tightly 
controlled (Latour 1991), managing these matters of medical 
concern is a complex affair. If, for instance, an infant arrives 
with signs and symptoms which do not point towards TB dis-
ease, they cannot be admitted to the CV ward. Rather, one of 
the nurses will refer the infant to one of TRO’s doctors, who 
handles the case as if the infant had been referred to TRO’s 
host hospital from one of the clinics in the surrounding com-
munities. In cases where a child develops an ailment after
admission, such as diarrhoea or a high temperature, the 
nurses still have to consult Dr Gilbert or one of TRO’s study 
doctors, but efforts will usually be made to treat the problem 
within the CV ward until it appears that referral to the host 
hospital is the wiser course of action. 
Notwithstanding the complexities of providing healthcare 
in the midst of an experiment, TRO’s CV ward’s links with 
more extensive healthcare resources allows earlier diagnoses 
and treatment than might otherwise be possible. Monique 
related one such example, reflecting also on the benefits of a 
visit to the CV ward:
One baby came in for failure to thrive. But when 
they [the nurses] did the physical exam, they could 
feel and see that around the abdomen there was 
some abnormality. They asked the study doc to do 
an assessment, and she found that there was a 
blockage, and they referred to the special 
paediatric outpatients. This baby ended up at 
Tygerberg hospital with colon problems. So ja, it’s 
good for the infants: a free x-ray, HIV-test, 
quantiFERON, and we look at the overall health of 
babies. 
Monique further told me that the possibility of earlier diagno-
sis and treatment is not restricted to the infants themselves, 
but also extended to the infants’ mothers:
If a mum is coughing, you can see, we are all nurses, 
you can see someone’s body language or facial 
expression when it’s not well. So in informed 
consent, we’ll ask if they’re happy, you don’t look 
satisfied, happy, are there any issues you’d like to 
discuss? They’ll say, yes I’m worried about 
someone at home, I can’t really stay for 2 days, or 
say I’m not feeling well, pain somewhere, I’m also 
coughing. So the nurse will ask Dr Gilbert or 
another doctor if we can do a chest x-ray, and they 
never refuse. The other night the night staff called 
to say it seems a mother might have breast cancer, 
a swollen painful breast ... So we let her call family 
to fetch her on the first evening ... She went to 
[another nearby] hospital. If they’re coughing, or a 
skin rash, Dr Gilbert will also always try to 
prescribe something for them. That’s the cool part. 
Henderson (2011:65-6), on the basis of prolonged ethno-
graphic encounters with people afflicted with AIDS, argues 
that the most valuable practices and relationships of care are 
enabled when those who are suffering can discuss things in 
their own time and on their own terms. One of the major 
successes of TRO’s researchers in this regard (both in the CV 
ward and during the follow-up visits) has been to listen atten-
tively to their participants and participants’ relatives. While 
they could fulfil the requirements of protocol largely by ‘tick-
ing boxes’ they often put the ‘form’ aside and acknowledge 
the human beings in front of them. 
Yet, the relationship between experiment and care in the 
midst of TRO’s endeavours is not complementary in all 
respects. Monique believed that, given that each enrolled 
infant is a part of the study for the first two years of their 
lives, some of the infants who come through the CV ward are 
old enough to remember the stay: “They’re not babies any-
more – they are old enough to remember, and they get 
affected.” While the often unpleasant requirements of the CV 
ward visits might confer many benefits, Monique was con-
cerned that some infants are admitted repeatedly to the CV 
ward when there is actually no need. She pointed out that 
one of the primary grounds for these infants being brought 
into the CV ward is their being underweight – which explains, 
at least, the frequency with which infants are weighed 
through their first years of life. However, she argued, whilst 
being underweight is one of the primary clinical signs of child-
hood TB, the fact that these infants are coming in repeatedly 
and found not to have TB – even by the more cautious clinical 
diagnostic mechanisms – is evidence that the weight loss is 
caused by other factors affecting their wellbeing. If they have 
foetal alcohol syndrome, for instance – a tragically common 
occurrence in South Africa – the infant is never going to be of 
a normal weight, “even if they live in the king’s castle.” More 
often, the underlying cause of being chronically underweight 
is simply under- or malnourishment. 
Efforts have been made, however, to prevent infants 
returning to the CV ward for repeated stays. TRO cannot do 
much about infants with foetal alcohol syndrome besides 
acknowledging the condition when deciding whether to 
admit them to the CV ward. However, measures have been 
3. This is named after Professor Maurice Kibel of the University of Cape Town.
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taken to improve the nutrition of underweight infants. As 
Monique recounted, the primary endeavour has been to put 
infants flagged as under- or malnourished on government 
feeding schemes, which are designed to ensure that they are 
connected to a consistent source of sustenance. Moreover, as 
was discussed above, efforts are being made to increase the 
follow-up visit teams’ vigilance for factors of malnutrition that 
could cause infants to be losing weight or gaining it too slowly. 
Whilst largely ad hoc, and often unforeseen at the outset of 
the trial, these are instances of the kinds of “tinkering” that, 
according to Mol (2008:14), characterise the reality of care-
giving relationships on the ground. The efficacy of these 
measures is certainly questionable: in addition to the issues 
discussed above, there is debate as to the extent to which 
infants actually receive the sustenance provided by the gov-
ernment feeding schemes. Yet, it is through tinkering with the 
resources available in the moment that TRO’s researchers 
are able to negotiate, reconcile and ultimately improve both 
their protocol and ‘extra-protocol’ operations. 
Experiment and care: an uneasy union
Latour (1991) has long argued that behind the ‘objective’ 
front often worn by scientific institutions can be found the 
complexities, place specificities and, perhaps most impor-
tantly, sociality inherent in their operations. A particular irony 
of the clinical trials industry is that, the more a researcher 
aims to accumulate data in the interests of such paradigmatic 
scientific values as reliability, validity and that most notorious 
one, objectivity, the more subjectivity the researcher encoun-
ters. The tensions inherent in this state of affairs as clinical tri-
als ‘go global’ are the topic of a burgeoning body of literature 
in the social sciences. One of the most important observa-
tions made has been that ‘Big Pharma’, aided by the advent of 
CROs, is powerful enough to manipulate the global variability 
in regulatory standards to subject vulnerable people and pop-
ulations to their prospective products (Petryna 2005, 2007, 
2009). Yet, whilst gaping structural inequalities cast a long 
shadow over the conduct of clinical trials, current literature 
on practices of care (Mol 2006, 2008; Mol, Moser and Pols 
2010; Henderson 2011; Hardon et al. 2011) recommends 
further ethnographic engagement with the particularities of 
diseases ‘under the microscope’, the local contexts and histo-
ries in which they are entwined, and how these inform the 
affective relationships between clinical research organisations 
and their participants. These are integral elements of the 
complex ecologies of care generated by clinical trials, and are 
thus important if we are to understand the challenges posed 
by the ground-level operations of the industry and to suggest 
meaningful solutions to those challenges. 
My findings at TRO’s field office suggest that the chal-
lenges its researchers faced in negotiating the day-to-day 
demands of protocol – and indeed ‘extra-protocol’ – are 
inseparable from the particularities of TB disease as a histori-
cal phenomenon in South Africa, the legacy of apartheid gov-
ernance which has left the majority of TRO’s participants in 
near-absolute poverty, and the prevailing political-economic 
conditions within which TRO operates. Fostering an holistic 
awareness for medical matters in the midst of poor living 
conditions; striking a balance between protocol and ‘extra-
protocol’ with limited time and resources; negotiating legal 
requirements in difficult conditions; responding well when 
the requirements of protocol seem uncaring – these are 
some of the challenges that punctuate the ecology of care 
generated by TRO’s clinical trials. They are specific to TRO 
and thus, in a sense, not generalisable. Yet, as Mol (2008:9) 
eloquently argues of her case study of practices of care in a 
hospital in the Netherlands: 
This is not to say that its relevance is local. A case 
study is of wider interest as it becomes a part of a 
trajectory. It offers points of contrast, comparison 
or reference for other sites and situations. It does 
not tell us what to expect – or do – anywhere else, 
but it does suggest pertinent questions. Case 
studies increase our sensitivity. It is the very 
specificity of a meticulously studied case that allows 
us to unravel what remains the same and what 
changes from one situation to the next.
Although place-specific, the details of TRO’s endeavours can 
serve as a point of comparison or reference for other locali-
ties of clinical research, especially those in resource-poor set-
tings where interventions are arguably most urgently needed. 
What I would like to encourage is a greater collection of thick 
ethnographic accounts, the conversations between which will 
hopefully enhance our ability to suggest ground-level solu-
tions to particular challenges in particular research localities.
I would like to offer one further suggestion for future eth-
nographic research on clinical trials. Mol (2008) advanced her 
arguments about the on-going processes of tinkering that 
characterise healthcare provision in the context of her 
engagement with chronic illness and the multiple actors 
involved therewith. TRO’s endeavours suggest that ‘tinker-
ing’, as a reality of providing and improving care, might well 
operate on larger scales too. As anthropologists, we are of 
course hesitant to read too much into notions such as ‘com-
munity’. Yet, while the interactions between TRO’s research-
ers and their participants are usually quite fleeting – at least 
compared to relations of chronic illness – these interactions 
with what are largely referred to by TRO’s researchers as 
“the community” have spanned nearly 12 years. TRO’s rela-
tionship with ‘the community’ has involved much tinkering 
over that period. It is at least partially in virtue of this that 
TRO is still generally trusted in and around the region. I sug-
gest that the acknowledgement of tinkering manoeuvres at 
different scales might prove useful in further exploring the ins 
and outs of the clinical trials industry on the ground. 
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